메뉴 건너뛰기




Volumn 30, Issue 11, 2011, Pages

Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine

Author keywords

adolescent; antibody ersistence; booster; meningococcus; vaccine

Indexed keywords

BACTERIUM ANTIBODY; GLYCOCONJUGATE; IMMUNOGLOBULIN G; MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

EID: 80055005675     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318224fb14     Document Type: Article
Times cited : (11)

References (25)
  • 1
    • 77951625637 scopus 로고    scopus 로고
    • Epidemiological profile of meningococcal disease in the United States
    • Harrison L. Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis. 2010;50(suppl 2):S37-S44.
    • (2010) Clin Infect Dis , vol.50 , Issue.SUPPL. 2
    • Harrison, L.1
  • 2
    • 77952004260 scopus 로고    scopus 로고
    • Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: Effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity
    • Campbell H, Andrews N, Borrow R, et al. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol. 2010;17:840-847.
    • (2010) Clin Vaccine Immunol , vol.17 , pp. 840-847
    • Campbell, H.1    Andrews, N.2    Borrow, R.3
  • 4
    • 3242768475 scopus 로고    scopus 로고
    • Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction
    • DOI 10.1016/S0140-6736(04)16725-1, PII S0140673604167251
    • Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet. 2004;364:365-367. (Pubitemid 38970013)
    • (2004) Lancet , vol.364 , Issue.9431 , pp. 365-367
    • Trotter, C.L.1    Andrews, N.J.2    Kaczmarski, E.B.3    Miller, E.4    Ramsay, M.E.5
  • 5
    • 74549171099 scopus 로고    scopus 로고
    • Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae Type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine
    • Borrow R, Andrews N, Findlow H, et al. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae Type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol. 2010;17:154-159.
    • (2010) Clin Vaccine Immunol , vol.17 , pp. 154-159
    • Borrow, R.1    Andrews, N.2    Findlow, H.3
  • 6
    • 79951681571 scopus 로고    scopus 로고
    • Persistence of immunity following a booster dose of a Haemophilus influenzae type B-meningococcal serogroup C glycoconjugate vaccine: Follow-up of a randomized controlled trial
    • Khatami A, Snape MD, John T, et al. Persistence of immunity following a booster dose of a Haemophilus influenzae type B-meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial. Pediatr Infect Dis J. 2011;30:197-202.
    • (2011) Pediatr Infect Dis J , vol.30 , pp. 197-202
    • Khatami, A.1    Snape, M.D.2    John, T.3
  • 7
    • 77952993552 scopus 로고    scopus 로고
    • Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primaryschool children in 1999-2000 and response to a booster: A phase 4 clinical trial
    • Perrett K, Winter A, Kibwana E, et al. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primaryschool children in 1999-2000 and response to a booster: a phase 4 clinical trial. Clin Infect Dis. 2010;50:1601-1610.
    • (2010) Clin Infect Dis , vol.50 , pp. 1601-1610
    • Perrett, K.1    Winter, A.2    Kibwana, E.3
  • 8
    • 55849138735 scopus 로고    scopus 로고
    • Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era
    • Trotter C, Borrow R, Findlow J, et al. Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era. Clin Vaccine Immunol. 2008;15:1694-1698.
    • (2008) Clin Vaccine Immunol , vol.15 , pp. 1694-1698
    • Trotter, C.1    Borrow, R.2    Findlow, J.3
  • 9
    • 61349145533 scopus 로고    scopus 로고
    • Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines
    • Pollard A, Perrett K, Beverley P. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol. 2009;9:213-220.
    • (2009) Nat Rev Immunol , vol.9 , pp. 213-220
    • Pollard, A.1    Perrett, K.2    Beverley, P.3
  • 10
    • 33751555760 scopus 로고    scopus 로고
    • Serogroup C meningococcal glycoconjugate vaccine in adolescents: Persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization
    • DOI 10.1086/508776
    • Snape MD, Kelly DF, Salt P, et al. Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin Infect Dis. 2006;43:1387-1394. (Pubitemid 44845637)
    • (2006) Clinical Infectious Diseases , vol.43 , Issue.11 , pp. 1387-1394
    • Snape, M.D.1    Kelly, D.F.2    Salt, P.3    Green, S.4    Snowden, C.5    Diggle, L.6    Borkowski, A.7    Yu, L.-M.8    Moxon, E.R.9    Pollard, A.J.10
  • 11
    • 67649491062 scopus 로고    scopus 로고
    • Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine
    • Sakou I-I, Tzanakaki G, Tsolia M, et al. Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine. Vaccine. 2009;27:4408-4411.
    • (2009) Vaccine , vol.27 , pp. 4408-4411
    • Sakou, I.-I.1    Tzanakaki, G.2    Tsolia, M.3
  • 12
    • 33644884439 scopus 로고    scopus 로고
    • Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine
    • Vu D, Welsch J, Zuno-Mitchell P, et al. Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine. J Infect Dis. 2006;193:821-828.
    • (2006) J Infect Dis , vol.193 , pp. 821-828
    • Vu, D.1    Welsch, J.2    Zuno-Mitchell, P.3
  • 13
    • 33750629955 scopus 로고    scopus 로고
    • CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells
    • Kelly D, Snape M, Clutterbuck E, et al. CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells. Blood. 2006;108:2642-2647.
    • (2006) Blood , vol.108 , pp. 2642-2647
    • Kelly, D.1    Snape, M.2    Clutterbuck, E.3
  • 16
    • 67349179167 scopus 로고    scopus 로고
    • Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease
    • Frasch C, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine. 2009; 27(suppl 2):B112-B116.
    • (2009) Vaccine , vol.27 , Issue.SUPPL. 2
    • Frasch, C.1    Borrow, R.2    Donnelly, J.3
  • 18
    • 34548719417 scopus 로고    scopus 로고
    • Reconsideration of the use of meningococcal polysaccharide vaccine
    • DOI 10.1097/INF.0b013e3180cc2c25, PII 0000645420070800000011
    • Granoff D, Pollard A. Reconsideration of the use of meningococcal polysaccharide vaccine. Pediatr Infect Dis J. 2007;26:716-722. (Pubitemid 47424642)
    • (2007) Pediatric Infectious Disease Journal , vol.26 , Issue.8 , pp. 716-722
    • Granoff, D.M.1    Pollard, A.J.2
  • 19
    • 33745271338 scopus 로고    scopus 로고
    • Modeling future changes to the meningococcal serogroup C conjugate (MCC) vaccine program in England and Wales
    • Trotter C, Edmunds W, Ramsay M, et al. Modeling future changes to the meningococcal serogroup C conjugate (MCC) vaccine program in England and Wales. Hum Vaccin. 2006;2:68-73. (Pubitemid 43927160)
    • (2006) Human Vaccines , vol.2 , Issue.2 , pp. 68-73
    • Trotter, C.L.1    Edmunds, W.J.2    Ramsay, M.E.3    Miller, E.4
  • 20
    • 49749096045 scopus 로고    scopus 로고
    • Meningococcal C booster not recommended by evidence
    • Thomas H, Andrews N, Trotter C, et al. Meningococcal C booster not recommended by evidence. Br Med J. 2008;337:a1139.
    • (2008) Br Med J , vol.337
    • Thomas, H.1    Andrews, N.2    Trotter, C.3
  • 21
    • 79951871167 scopus 로고    scopus 로고
    • Adolescent immunisation: The next big thing?
    • Finn A, Clarke E, Mytton J. Adolescent immunisation: the next big thing? Arch Dis Child. 2011;96:497-499.
    • (2011) Arch Dis Child , vol.96 , pp. 497-499
    • Finn, A.1    Clarke, E.2    Mytton, J.3
  • 22
    • 79954624170 scopus 로고    scopus 로고
    • Immunisation of adolescents in the UK
    • Kale AR, Snape MD. Immunisation of adolescents in the UK. Arch Dis Child. 2011;96:492-495.
    • (2011) Arch Dis Child , vol.96 , pp. 492-495
    • Kale, A.R.1    Snape, M.D.2
  • 23
    • 65349110862 scopus 로고    scopus 로고
    • Update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations: An advisory committee statement
    • Immunization NACo
    • Immunization NACo. Update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations: an advisory committee statement. Can Commun Dis Rep. 2009; 35(ACS-3):1-40.
    • (2009) Can Commun Dis Rep , vol.35 , Issue.ACS-3 , pp. 1-40
  • 24
    • 34250819829 scopus 로고    scopus 로고
    • Vaccinating adolescents against meningococcal disease in Canada: A cost-effectiveness analysis
    • DOI 10.1016/j.vaccine.2007.04.071, PII S0264410X07004781
    • De Wals P, Coudeville L, Trottier P, et al. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis. Vaccine. 2007;25:5433-5440. (Pubitemid 46977525)
    • (2007) Vaccine , vol.25 , Issue.29 , pp. 5433-5440
    • De Wals, P.1    Coudeville, L.2    Trottier, P.3    Chevat, C.4    Erickson, L.J.5    Nguyen, V.H.6
  • 25
    • 79251607440 scopus 로고    scopus 로고
    • Updated recommendations for use of meningococcal conjugate vaccines-Advisory Committee on Immunization Practices (ACIP), 2010
    • Centers for Disease Control and Prevention
    • Centers for Disease Control and Prevention. Updated recommendations for use of meningococcal conjugate vaccines-Advisory Committee on Immunization Practices (ACIP), 2010. Morbid Mortal Wkly Rep. 2011:72-76.
    • (2011) Morbid Mortal Wkly Rep. , pp. 72-76


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.